Ixekizumab

Details

Files
Generic Name:
Ixekizumab
Project Status:
Complete
Therapeutic Area:
Psoriasis, moderate to severe plaque
Manufacturer:
Eli Lilly Canada Inc.
Call for patient/clinician input open:
Brand Name:
Taltz
Project Line:
Reimbursement Review
Project Number:
SR0481-000
Call for patient/clinician input closed:
NOC Status at Filing:
Pre NOC
Submission Type:
Initial
Indications:
Psoriasis, moderate to severe plaque
Recommendation Type:
Reimburse with clinical criteria and/or conditions
Final Recommendation: